The Pompe Disease Content Hub Channel

VAL-1221 in the Treatment of Pompe Disease

Dustin Armstrong, PhD, president of Parasail, LLC, discusses VAL-1221, a combination of an antibody and enzyme replacement therapy, for treating Pompe disease. According to Dr Armstrong, VAL-1221 facilitates transport of the enzyme to extra-lysosomal and lysosomal storage of glycogen in cells. A phase 1/2 trial is currently underway.

More in Pompe Disease Content Hub

► 13:25

An Overview of Research Program for Pompe Disease

Pompe Disease Content Hub

Priya Kishnani, MD, Chen Family Professor of Pediatrics, Chief of the Division of Medical Genetics, Duke University Medical Center, and Medical Director of the YT and Alice Chen Pediatric Genetic...

► 1:37:47

Small Molecule Inhibitor Reduces Glycogen in Preclinical Mouse Models of Pompe Disease

Pompe Disease Content Hub

Julie Ullman, PhD, of Maze Therapeutics, discusses a new investigational drug, MZE001, that is a small molecule inhibitor of glycogen synthase 1 (GSY1) for the treatment of Pompe disease during...

► 02:10

Multidisciplinary Approach to Managing Pompe Disease

Pompe Disease Content Hub

Priya Kishnani, MD, Chen Family Professor of Pediatrics, Chief of the Division of Medical Genetics, Duke University Medical Center, and Medical Director of the YT and Alice Chen Pediatric Genetic...

► 54:32

Newborn Screening for Pompe Disease

Pompe Disease Content Hub

Damara Ortiz, MD, Director of the Lysosomal Storage Diseases Program at the University of Pittsburgh Medical Center discusses newborn screening for Pompe disease and mucopolysaccharidosis type 1. She presents an...